Neuronostics

Bristol-based health tech firm Neuronostics has secured £3 million in a new funding round, co-led by Empirical Ventures and The FSE Group, with participation from several other investors. The capital infusion will be used to accelerate its BioEP digital biomarker platform, designed for advanced epilepsy diagnosis and prognosis, and to pursue US regulatory approval.

Summary of transaction details:

• Value: £3,000,000
• Sector: Healthcare & Biotech (Medtech)
• Advisor: N/A
• Key Entities: Target: Neuronostics; Lead Investors: Empirical Ventures, The FSE Group; Other Investors: British Business Bank’s South West Investment Fund, Ascension Ventures, QantX, New Wave Venture Partners, Angel Investors Bristol
• Location: Bristol, UK (Target Company)

Note: This funding round is set to accelerate the development and commercialisation of BioEP, Neuronostics' patented digital biomarker platform for epilepsy diagnosis and prognosis, addressing critical needs in patient diagnosis and treatment pathways by aiming to reduce diagnostic wait times and misdiagnosis rates.